search
Back to results

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer (13-Cis)

Primary Purpose

Drug Toxicity, Lung Cancer

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
13-cis retinoic acid
Tocopherol
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Drug Toxicity focused on measuring non-small cell lung cancer, small cell lung cancer, drug/agent toxicity by tissue/organ

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients identified through the Tissue Procurement/Screening Project with mild, moderate or severe dysplasia, Ca In situ OR surgically cured patients with head and neck cancer who are found to have mild atypia or greater on their staging bronchoscopy. (This includes carcinoma in situ). Also eligible are patients with Stage I and II non-small cell lung cancer who are disease free greater than 36 months. Patients must have at least a 30 pack year smoking history. Patients must be a current smoker or ex-smoker who have not smoked for at least 6 months more. Patients must have peripheral granulocyte count of > 1500 and platelet count of > 150,000. Patients must have adequate hepatic function with bilirubin < 1.5 mg % and SGPT < 4 times institutional upper limits of normal. Patients must have adequate renal function with serum creatinine < 1.5 mg %. All patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines. Exclusion Criteria: Patients must not have a current or past history of cancer within the past 5 years with the exception of surgically cured head and neck cancer or surgically cured Stage I or II lung cancer > 36 months from diagnosis or skin cancer or in situ cancers. Patients must have no serious intercurrent illness including insulin dependent diabetes mellitus or hypercholesterolemia (>239mg/dl) / hypertriglyceridemia (>149mg/dl). Patients must not have evidence of clinically active coronary artery disease including myocardial infarction within 6 weeks, chest pain or poorly controlled congestive heart failure or any other serious medical condition, which would preclude a patient from undergoing a bronchoscopy. Patients must not have cardiac dysrhythmia that is potentially life threatening such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well controlled atrial fibrillation or rare (<2/minute) premature ventricular contractions are not exclusionary Chest x-ray must not show evidence of tumor. Patients must not be taking vitamin A or E supplements Patients must not be taking tetracycline or minocycline. Patients who have had prior chemotherapy or radiation therapy. Women who are pregnant are ineligible

Sites / Locations

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center
  • National Jewish Center for Immunology and Respiratory Medicine
  • Lung Cancer Institute
  • Veterans Affairs Medical Center - Denver

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

13-cis retinoic acid

13-Cis Retinoic Acid and Tocopherol

Observation

Arm Description

13-cis retinoic acid 50 mg/d

13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)

Observation

Outcomes

Primary Outcome Measures

Treatment failure
Treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy

Secondary Outcome Measures

Full Information

First Posted
November 1, 1999
Last Updated
May 13, 2020
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT00002586
Brief Title
13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
Acronym
13-Cis
Official Title
ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
January 1993 (undefined)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.
Detailed Description
OBJECTIVES: To determine if alpha tocopherol can reduce the toxicities of low dose 13-cis retinoic acid administered for one year. To access the adequacy of the collected specimens for studies of intermediate endpoint markers. to establish a depository of biologic specimens for future studies of new biomarkers. Arm 1: Patients receive oral 13-cis retinoic acid daily. Arm 2: Patients receive oral 13-cis retinoic acid and oral vitamin E daily. Arm 3: Patients undergo observation only. Treatment continues in arms I and II for 1 year in the absence of unacceptable toxicity. Patients are followed annually for 2 years. PROJECTED ACCRUAL: A total of 100 patients (33 Arm 1, 33 Arm 2, and 34 Arm 3) will be accrued for this study within 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Drug Toxicity, Lung Cancer
Keywords
non-small cell lung cancer, small cell lung cancer, drug/agent toxicity by tissue/organ

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
13-cis retinoic acid
Arm Type
Experimental
Arm Description
13-cis retinoic acid 50 mg/d
Arm Title
13-Cis Retinoic Acid and Tocopherol
Arm Type
Experimental
Arm Description
13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
Arm Title
Observation
Arm Type
No Intervention
Arm Description
Observation
Intervention Type
Drug
Intervention Name(s)
13-cis retinoic acid
Other Intervention Name(s)
Isotretinoin, AccutaneT
Intervention Type
Dietary Supplement
Intervention Name(s)
Tocopherol
Other Intervention Name(s)
Vitamin E
Primary Outcome Measure Information:
Title
Treatment failure
Description
Treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy
Time Frame
Three years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients identified through the Tissue Procurement/Screening Project with mild, moderate or severe dysplasia, Ca In situ OR surgically cured patients with head and neck cancer who are found to have mild atypia or greater on their staging bronchoscopy. (This includes carcinoma in situ). Also eligible are patients with Stage I and II non-small cell lung cancer who are disease free greater than 36 months. Patients must have at least a 30 pack year smoking history. Patients must be a current smoker or ex-smoker who have not smoked for at least 6 months more. Patients must have peripheral granulocyte count of > 1500 and platelet count of > 150,000. Patients must have adequate hepatic function with bilirubin < 1.5 mg % and SGPT < 4 times institutional upper limits of normal. Patients must have adequate renal function with serum creatinine < 1.5 mg %. All patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines. Exclusion Criteria: Patients must not have a current or past history of cancer within the past 5 years with the exception of surgically cured head and neck cancer or surgically cured Stage I or II lung cancer > 36 months from diagnosis or skin cancer or in situ cancers. Patients must have no serious intercurrent illness including insulin dependent diabetes mellitus or hypercholesterolemia (>239mg/dl) / hypertriglyceridemia (>149mg/dl). Patients must not have evidence of clinically active coronary artery disease including myocardial infarction within 6 weeks, chest pain or poorly controlled congestive heart failure or any other serious medical condition, which would preclude a patient from undergoing a bronchoscopy. Patients must not have cardiac dysrhythmia that is potentially life threatening such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well controlled atrial fibrillation or rare (<2/minute) premature ventricular contractions are not exclusionary Chest x-ray must not show evidence of tumor. Patients must not be taking vitamin A or E supplements Patients must not be taking tetracycline or minocycline. Patients who have had prior chemotherapy or radiation therapy. Women who are pregnant are ineligible
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
York E. Miller, MD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Cancer Center at University of Colorado Health Sciences Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80010
Country
United States
Facility Name
National Jewish Center for Immunology and Respiratory Medicine
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Lung Cancer Institute
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Veterans Affairs Medical Center - Denver
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19401528
Citation
Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.
Results Reference
result

Learn more about this trial

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

We'll reach out to this number within 24 hrs